416 related articles for article (PubMed ID: 28770274)
1. A pilot study for texture analysis of
Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of Texture Analysis of Primary Tumor [
Nakajo M; Jinguji M; Shinaji T; Aoki M; Tani A; Nakabeppu Y; Nakajo M; Sato M; Yoshiura T
Mol Imaging Biol; 2019 Aug; 21(4):771-780. PubMed ID: 30397859
[TBL] [Abstract][Full Text] [Related]
3. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT.
Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Nihara T; Fukukura Y; Yoshiura T
Abdom Radiol (NY); 2017 Apr; 42(4):1210-1221. PubMed ID: 27891549
[TBL] [Abstract][Full Text] [Related]
5. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity index evaluated by slope of linear regression on
Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
8. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on
Liu X; Xiang K; Geng GY; Wang SC; Ni M; Zhang YF; Pan HF; Lv WF
Contrast Media Mol Imaging; 2022; 2022():2586245. PubMed ID: 35173559
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
[TBL] [Abstract][Full Text] [Related]
14.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.
Lovinfosse P; Polus M; Van Daele D; Martinive P; Daenen F; Hatt M; Visvikis D; Koopmansch B; Lambert F; Coimbra C; Seidel L; Albert A; Delvenne P; Hustinx R
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):365-375. PubMed ID: 29046927
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.
Nakajo M; Nakajo M; Kajiya Y; Jinguji M; Nishimata N; Shimaoka S; Nihara T; Aridome K; Tanaka S; Fukukura Y; Tani A; Koriyama C
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1223-32. PubMed ID: 23653240
[TBL] [Abstract][Full Text] [Related]
19. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
20. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
